Pfizer’s multi-year lows reflect headwinds, lack of catalysts, and fading appeal to both growth and defensive investors. Read ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Pfizer offers a substantial 6.7% dividend yield and has increased its dividend for 16 consecutive years. The stock trades at a forward P/E of just 8.7, close to historical lows. Despite policy ...

Pfizer PFE underwent analysis by 4 analysts in the last quarter ... While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pfizer (PFE – Research Report), Nanobiotix (NBTX – Research ...

Pfizer and Allergan have confirmed that they ... driven by the potential savings they are able to deliver to healthcare systems. The ISPE Singapore Affiliate Conference & Exhibition is one of ...

Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors ...

Undoubtedly the biggest story of the week was the scrapping of the $160 billion merger between Pfizer and Allergan ... says WHO The World Health Organisation (WHO) released a report into worldwide ...

What Happened? A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous ...

In recent developments, a class action lawsuit was filed against Cerevel Therapeutics, Bain Capital Investors, and Pfizer ...

Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon ...

Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't entirely warranted. Pharmaceutical titan Pfizer (NYSE: PFE) is a case in point.